The aim of this observational retrospective study is to evaluate the effect ofsupplementation with cholecalciferol D3 in reducing the risk of: - occurence of Long COVID syndrome after acute COVID-19 illness - occurence of SARS-CoV-2 infection after anti-COVID-19 vaccination
Anamnestic, laboratory and therapeutic data will be collected during outpatient visits.
Inclusion Criteria (For aim I):
- age ≥18
- outpatient with first visit on Endocrinology Department performed from 01/01/2020 to
31/12/2022
- previous SARS CoV-2 infection
- clinical,anamnestic and therapeutic data 6 months post SARS CoV-2 infection
- data on cholecalciferol supplementation
- signature of informed consent
Exclusion Criteria (For aim I):
- age ≤ 18
- pregnant or breastfeeding women
- patients suffering from primary and/or acquired immunodeficiency and/or severe
impairment of general clinical conditions
- patients treated with drugs that interfere with vitamin D metabolism
- first vaccination anti Sars COVID performed before the acute infection
- first vaccination performed within 6 months of the acute infection
- patients unable to sign the informed consent
Inclusion Criteria (For aim 2)
-- age ≥18
- outpatient with first visit on Endocrinology Department performed from 01/01/2020 to
31/12/2022
- vaccination with BNT162b2 Biontec mRNA Pfizer/BioNtech
- clinical, anamnestic and therapeutic data 6 months post SARS CoV-2 infection
- data on cholecalciferol supplementation
- signature of informed consent
Exclusion Criteria (For aim 2):
- age ≤ 18
- pregnant or breastfeeding women
- patients suffering from primary and/or acquired immunodeficiency and/or severe
impairment of general clinical conditions
- patients treated with drugs that interfere with vitamin D metabolism
- additional vaccination performed before 6-12 months
- acute infection before the vaccination
- patients unable to sign the informed consent
Luigi di Filippo
Milan, Italy
Not Provided